<!doctype html><html class=no-js lang=en><head><meta charset=UTF-8><meta name=viewport content="width=device-width,initial-scale=1"><title>ALS渐冻症临床失败的秘密被最新蛋白组学技术解开！ - 文字轨迹</title>
<script>(function(e,t){e[t]=e[t].replace("no-js","js")})(document.documentElement,"className")</script><meta name=description content><meta property="og:url" content="https://ixxmu.github.io/posts/2025-09/als%E6%B8%90%E5%86%BB%E7%97%87%E4%B8%B4%E5%BA%8A%E5%A4%B1%E8%B4%A5%E7%9A%84%E7%A7%98%E5%AF%86%E8%A2%AB%E6%9C%80%E6%96%B0%E8%9B%8B%E7%99%BD%E7%BB%84%E5%AD%A6%E6%8A%80%E6%9C%AF%E8%A7%A3%E5%BC%80_/"><meta property="og:site_name" content="文字轨迹"><meta property="og:title" content="ALS渐冻症临床失败的秘密被最新蛋白组学技术解开！"><meta property="og:description" content="ALS渐冻症临床失败的秘密被最新蛋白组学技术解开！ by 循因缉药 我愿称之为：蛋白组学的魅力时刻2022年3月28日，渤健和合作伙伴Ionis Pharmaceuticals发布了肌萎缩侧索硬化症（ALS）的候选药物BIIB078临床试验结果：失败。"><meta property="og:locale" content="zh_cn"><meta property="og:type" content="article"><meta property="article:section" content="posts"><meta property="article:published_time" content="2025-09-03T06:00:29+00:00"><meta property="article:modified_time" content="2025-09-03T06:00:29+00:00"><meta property="article:tag" content="Fetched"><meta property="article:tag" content="循因缉药"><meta itemprop=name content="ALS渐冻症临床失败的秘密被最新蛋白组学技术解开！"><meta itemprop=description content="ALS渐冻症临床失败的秘密被最新蛋白组学技术解开！ by 循因缉药 我愿称之为：蛋白组学的魅力时刻2022年3月28日，渤健和合作伙伴Ionis Pharmaceuticals发布了肌萎缩侧索硬化症（ALS）的候选药物BIIB078临床试验结果：失败。"><meta itemprop=datePublished content="2025-09-03T06:00:29+00:00"><meta itemprop=dateModified content="2025-09-03T06:00:29+00:00"><meta itemprop=wordCount content="123"><meta itemprop=keywords content="Fetched,循因缉药"><meta name=twitter:card content="summary"><meta name=twitter:title content="ALS渐冻症临床失败的秘密被最新蛋白组学技术解开！"><meta name=twitter:description content="ALS渐冻症临床失败的秘密被最新蛋白组学技术解开！ by 循因缉药 我愿称之为：蛋白组学的魅力时刻2022年3月28日，渤健和合作伙伴Ionis Pharmaceuticals发布了肌萎缩侧索硬化症（ALS）的候选药物BIIB078临床试验结果：失败。"><link rel=preconnect href=https://fonts.gstatic.com crossorigin><link rel=dns-prefetch href=//fonts.googleapis.com><link rel=dns-prefetch href=//fonts.gstatic.com><link rel=stylesheet href="https://fonts.googleapis.com/css?family=Open+Sans:400,400i,700"><link rel=stylesheet href=../../../css/style.css><link rel=stylesheet href=../../../css/custom.css><link rel="shortcut icon" href=../../../favicon.ico></head><body class=body><div class="container container--outer"><header class=header><div class="container header__container"><div class=logo><a class=logo__link href=../../../ title=文字轨迹 rel=home><div class="logo__item logo__text"><div class=logo__title>文字轨迹</div><div class=logo__tagline>故事流淌过的地方</div></div></a></div><nav class=menu><button class=menu__btn aria-haspopup=true aria-expanded=false tabindex=0>
<span class=menu__btn-title tabindex=-1>Menu</span></button><ul class=menu__list><li class=menu__item><a class=menu__link href=../../../posts/><span class=menu__text>文章</span></a></li><li class=menu__item><a class=menu__link href=../../../tags/><span class=menu__text>标签</span></a></li><li class=menu__item><a class=menu__link href=../../../about/><span class=menu__text>关于</span></a></li></ul></nav></div></header><div class="wrapper flex"><div class=primary><main class=main role=main><article class=post><header class=post__header><meta name=referrer content="never"><h1 class=post__title>ALS渐冻症临床失败的秘密被最新蛋白组学技术解开！</h1><div class="post__meta meta"><div class="meta__item-datetime meta__item"><svg class="meta__icon icon icon-time" width="16" height="14" viewBox="0 0 30 28"><path d="M15 0a14 14 0 110 28 1 1 0 010-28m0 3a3 3 0 100 22 3 3 0 000-22m1 4h-2v8.4l6.8 4.4L22 18l-6-3.8z"/></svg><time class=meta__text datetime=2025-09-03T06:00:29Z>2025-09-03</time></div><div class="meta__item-categories meta__item"><svg class="meta__icon icon icon-category" width="16" height="16" viewBox="0 0 16 16"><path d="m7 2 1 2h8v11H0V2z"/></svg><span class=meta__text><a class=meta__link href=../../../categories/duty/ rel=category>Duty</a></span></div><div class="meta__item-author meta__item"><svg class="meta__icon icon icon-author" width="16" height="16" viewBox="0 0 16 16"><path d="M8 1c2 0 3.5 2 3.5 4.5S10 9 10 9c3 1 4 2 4 6H2c0-4 1-5 4-6 0 0-1.5-1-1.5-3.5S6 1 8 1"/></svg><span class=meta__text>Bloger</span></div></div></header><div class="post__toc toc"><div class=toc__title>Page content</div><div class=toc__menu><nav id=TableOfContents><ul><li><a href=#als渐冻症临床失败的秘密被最新蛋白组学技术解开-by-循因缉药>ALS渐冻症临床失败的秘密被最新蛋白组学技术解开！ by 循因缉药</a></li></ul></nav></div></div><div class="content post__content clearfix"><h2 id=als渐冻症临床失败的秘密被最新蛋白组学技术解开-by-循因缉药>ALS渐冻症临床失败的秘密被最新蛋白组学技术解开！ by 循因缉药</h2><div><section mpa-from-tpl=t data-mpa-action-id=mf1wil9015cr data-pm-slice="0 0 []"><span leaf mpa-font-style=mf1wkzuo24w9 data-mpa-action-id=mf1wkzv81dy0 data-pm-slice="0 0 []"><span textstyle>我愿称之为：蛋白组学的魅力时刻</span></span></section><section data-mpa-template=t mpa-data-temp-power-by=yiban.io mpa-from-tpl=t data-mpa-action-id=mf1wil90uzg><section mpa-data-temp-power-by=yiban.io mpa-from-tpl=t data-mpa-action-id=mew6g72l2276 data-pm-slice="0 0 []"><section mpa-from-tpl=t><section mpa-from-tpl=t><section mpa-from-tpl=t><section mpa-from-tpl=t><p><span leaf mpa-is-content=t>2022年3月28日，渤健和合作伙伴Ionis Pharmaceuticals发布了肌萎缩侧索硬化症（ALS）的候选药物BIIB078临床试验结果：失败。</span></p><p><span leaf mpa-is-content=t>一线结果显示：该药物并没有显示出临床益处。</span></p><p><span leaf mpa-is-content=t>因此，渤健和Ionis因此决定终止其临床试验。</span></p><p><span leaf mpa-is-content=t>但是，究竟为什么药物无效导致临床失败？直到最近这个秘密才被揭开。</span></p></section></section></section></section></section></section><section data-mpa-template=t mpa-data-temp-power-by=yiban.io mpa-from-tpl=t data-mpa-action-id=mf1wleyfzf3><section data-mid mpa-from-tpl=t><section data-mid mpa-from-tpl=t><section data-mid mpa-from-tpl=t nodeleaf><img data-src=https://mmbiz.qpic.cn/mmbiz_png/wbOfcvkM2SqC8YWOchic1cda37szmAeUGD1oJqm4OpTSWg6Wkycrp8BWZicg2vuOzRzwIenthJcY1ZQIvJRpNwnw/640 data-ratio=0.013793103448275862 data-w=580 src=https://mmbiz.qpic.cn/mmbiz_png/wbOfcvkM2SqC8YWOchic1cda37szmAeUGD1oJqm4OpTSWg6Wkycrp8BWZicg2vuOzRzwIenthJcY1ZQIvJRpNwnw/640></section></section></section></section><p data-pm-slice="0 0 []"><span><span leaf><span textstyle>2025年08月26日，美国埃默里大学联合梅奥诊所等研究团队在顶级期刊Cell上发表了题为《Molecular impact of antisense oligonucleotide therapy in C9orf72-associated ALS》的研究论文，深入剖析了反义寡核苷酸</span></span></span><span><span><span leaf><span textstyle>（Antisense Oligonucleotide, ASO）药物BIIB078在C9orf72突变的肌萎缩侧索硬化症（c9ALS）患者中的分子作用机制。</span><span textstyle>借助最新的</span></span></span></span><span data-pm-slice='1 1 ["para",{"tagName":"p","attributes":{"style":"-webkit-tap-highlight-color: transparent; margin: 0px 0px 8px; padding: 0px; outline: 0px; max-width: 100%; box-sizing: border-box !important; overflow-wrap: break-word !important; clear: both; min-height: 1em; color: rgba(0, 0, 0, 0.9); font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif; font-size: 17px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0.544px; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; visibility: visible;","data-pm-slice":"0 0 []"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><span leaf><span textstyle>NULISA</span></span></span><span><span leaf><span textstyle>超灵敏蛋白组学技术，研究者筛选鉴定了CCL26作为BIIB078的新型药效学</span></span></span><span data-pm-slice='1 1 ["para",{"tagName":"p","attributes":{"style":"-webkit-tap-highlight-color: transparent;margin: 0px 0px 8px;padding: 0px;outline: 0px;max-width: 100%;clear: both;min-height: 1em;color: rgba(0, 0, 0, 0.9);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-size: 17px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0.544px;orphans: 2;text-align: justify;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;visibility: visible;box-sizing: border-box !important;overflow-wrap: break-word !important;","data-pm-slice":"0 0 []"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><span leaf><span textstyle>（pharmacodynamic，PD）</span></span></span><span><span leaf><span textstyle>生物标志物</span></span></span><span><span leaf><span textstyle>，并强调ASO疗法亟需新的、可靠的生物标志物，这对未来ASO疗法设计和神经退行性疾病治疗具有重要指导作用，对其他复杂疾病的治疗也具有广泛的意义。</span></span></span></p><section nodeleaf data-mpa-action-id=mf1vjr3n1v1u data-pm-slice="0 0 []"><img data-src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb6YhfYWCYiap9eicHTibRiaTzkqW2zKEUPZHvNp0hmouRaccibeuyAD1JrTQ04mGVNvWicpw16K6mIm8huA/640?wx_fmt=png&amp;from=appmsg#imgIndex=0" data-ratio=0.7564814814814815 data-s=300,640 data-type=png data-w=1080 type=block data-imgfileid=100000653 src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb6YhfYWCYiap9eicHTibRiaTzkqW2zKEUPZHvNp0hmouRaccibeuyAD1JrTQ04mGVNvWicpw16K6mIm8huA/640?wx_fmt=png&amp;from=appmsg#imgIndex=0"></section><p data-pm-slice="0 0 []"><b><span><span leaf><span textstyle>研究背景</span></span></span></b></p><section><span><span leaf><span textstyle>肌萎缩侧索硬化症</span></span></span><span><span><span leaf><span textstyle>（</span></span></span><span><span leaf><span textstyle>Amyotrophic Lateral Sclerosis，</span></span></span></span><span><span leaf><span textstyle>ALS</span></span></span><span><span><span leaf><span textstyle>，渐冻</span></span></span><span><span leaf><span textstyle>症</span></span></span></span><span><span leaf><span textstyle>）是一种致</span></span></span><span><span leaf><span textstyle>命的进行性神经退行性疾病，其特征是运动皮层和脊髓运动神经元缺失。在所有</span></span></span><span><span leaf><span textstyle>ALS</span></span></span><span><span leaf><span textstyle>病例中，</span></span></span><i><span><span leaf><span textstyle>C9orf72</span></span></span></i><span><span leaf><span textstyle>基因的第一个内含子中</span></span></span><span><span leaf><span textstyle>G</span></span></span><sub><span><span leaf><span textstyle>4</span></span></span></sub><span><span leaf><span textstyle>C</span></span></span><sub><span><span leaf><span textstyle>2</span></span></span></sub><span><span leaf><span textstyle>重复序列的异常扩增是最常见的遗传原因，这种扩增导致了毒性</span></span></span><span><span leaf><span textstyle>RNA</span></span></span><span><span leaf><span textstyle>转录本和双肽重复蛋白（</span></span></span><span><span leaf><span textstyle>DPR</span></span></span><span><span leaf><span textstyle>）的产生，从而引发神经元损伤。</span></span></span></section><section><span><span leaf><span textstyle>针对这一明确病因，</span></span></span><span><span leaf><span textstyle>Biogen</span></span></span><span><span leaf><span textstyle>和</span></span></span><span><span leaf><span textstyle>Ionis</span></span></span><span><span leaf><span textstyle>公司联合开发了基于</span></span></span><span leaf><span textstyle>反义寡核苷酸</span></span><span><span><span leaf><span textstyle>（ASO）</span></span></span><span><span leaf><span textstyle>疗法的药物</span></span></span></span><span><span leaf><span textstyle>BII</span></span></span><span><span leaf><span textstyle>B078</span></span></span><span><span><span leaf><span textstyle>（</span></span></span><span><span leaf><span textstyle>通用名tadunersen）</span></span></span></span><span><span leaf><span textstyle>，这是一款靶向</span></span></span><i><span><span leaf><span textstyle>C9orf72</span></span></span></i><span><span leaf><span textstyle>的</span></span></span><span><span leaf><span textstyle>G</span></span></span><sub><span><span leaf><span textstyle>4</span></span></span></sub><span><span leaf><span textstyle>C</span></span></span><sub><span><span leaf><span textstyle>2</span></span></span></sub><span><span leaf><span textstyle>重复转录本的混合骨架“</span></span></span><span><span leaf><span textstyle>gapmer</span></span></span><span><span leaf><span textstyle>”型</span></span></span><span><span leaf><span textstyle>ASO</span></span></span><span><span leaf><span textstyle>，通过</span></span></span><span><span leaf><span textstyle>RNAase-H</span></span></span><span><span leaf><span textstyle>介导的剪切来降解毒性</span></span></span><span><span leaf><span textstyle>G</span></span></span><sub><span><span leaf><span textstyle>4</span></span></span></sub><span><span leaf><span textstyle>C</span></span></span><sub><span><span leaf><span textstyle>2</span></span></span></sub><span><span leaf><span textstyle>重复转录本。</span><span textstyle>尽管在临床前研究中，</span></span></span><span><span leaf><span textstyle>BIIB078</span></span></span><span><span leaf><span textstyle>能够沉默</span></span></span><span><span leaf><span textstyle>G</span></span></span><sub><span><span leaf><span textstyle>4</span></span></span></sub><span><span leaf><span textstyle>C</span></span></span><sub><span><span leaf><span textstyle>2</span></span></span></sub><span><span leaf><span textstyle>重复转录的表达和</span></span></span><span><span leaf><span textstyle>DPR</span></span></span><span><span leaf><span textstyle>的减</span></span></span><span><span><span leaf><span textstyle>少，但是临床试验因未能带来临床获益而终止。</span></span></span></span></section><p><span><span leaf><span textstyle>本研究旨在通过对接受</span></span></span><span><span leaf><span textstyle>BIIB078</span></span></span><span><span leaf><span textstyle>治疗的</span></span></span><span><span leaf><span textstyle>c9ALS</span></span></span><span><span leaf><span textstyle>患者进行多维度的分子和神经病理分析，明确</span></span></span><span><span leaf><span textstyle>BIIB078</span></span></span><span><span leaf><span textstyle>在中枢神经的分布特征、对疾病病理的影响、体内免疫应答及更优的药效标志物，为未来</span></span></span><span><span leaf><span textstyle>ASO</span></span></span><span><span leaf><span textstyle>疗法的优化提供重要依据。</span></span></span><p></p></p><p><b><span><span leaf><span textstyle>关键研究方法和结果</span></span></span><span><p></p></span></b></p><ul><li><b><span><span leaf><span textstyle>ASO</span></span></span></b><b><span><span leaf><span textstyle>治疗后</span></span></span><span><span leaf><span textstyle>c9ALS</span></span></span></b><b><span><span leaf><span textstyle>患者体液生物标志物分析</span></span></span></b><span><span leaf><span textstyle>：</span></span></span><span><span leaf><span textstyle>免疫测定ASO</span></span></span><span><span leaf><span textstyle>治疗后的</span></span></span><span><span leaf><span textstyle>c9ALS</span></span></span><span><span leaf><span textstyle>患者脑脊液中</span></span></span><span><span leaf><span textstyle>poly(GP)</span></span></span><span><span leaf><span textstyle>（</span></span></span><span><span leaf><span textstyle>DPR</span></span></span><span><span leaf><span textstyle>标志物）和</span></span></span><span><span leaf><span textstyle>BIIB078</span></span></span><span><span leaf><span textstyle>的含量，发现</span></span></span><span><span leaf><span textstyle>6</span></span></span><span><span leaf><span textstyle>例患者中有</span></span></span><span><span leaf><span textstyle>5</span></span></span><span><span leaf><span textstyle>例患者的</span></span></span><span><span leaf><span textstyle>poly(GP)</span></span></span><span><span leaf><span textstyle>降低（平均降低</span></span></span><span><span leaf><span textstyle>37.2%</span></span></span><span><span leaf><span textstyle>），但个体差异显著，且临床评分没有相关性（</span></span></span><span><span leaf><span textstyle>ALSFRS-R</span></span></span><span><span leaf><span textstyle>）。</span></span></span><span><span leaf><span textstyle>BIIB078</span></span></span><span><span leaf><span textstyle>的含量和</span></span></span><span><span leaf><span textstyle>poly(GP)</span></span></span><span><span leaf><span textstyle>的水平也呈现很大的个体差异，</span></span></span><span><span leaf><span textstyle>4</span></span></span><span><span leaf><span textstyle>例患者没有相关性，</span></span></span><span><span leaf><span textstyle>2</span></span></span><span><span leaf><span textstyle>例存在相关性，这说明</span></span></span><span><span leaf><span textstyle>poly(GP)</span></span></span><span><span leaf><span textstyle>并不是可靠的</span></span></span><span><span leaf><span textstyle>BIIB078</span></span></span><span><span leaf><span textstyle>药效评估指标。</span></span></span><p></p><b><span leaf><br></span></b></li></ul><section nodeleaf><img data-src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb6YhfYWCYiap9eicHTibRiaTzkq3Aaic0icmicvWPjUcDluYngVkHV5tBqrDBBHddibyJ78aNhvSbF2odoDuw/640?wx_fmt=png&amp;from=appmsg#imgIndex=1" data-ratio=0.3574074074074074 data-s=300,640 data-type=png data-w=1080 type=block data-imgfileid=100000657 src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb6YhfYWCYiap9eicHTibRiaTzkq3Aaic0icmicvWPjUcDluYngVkHV5tBqrDBBHddibyJ78aNhvSbF2odoDuw/640?wx_fmt=png&amp;from=appmsg#imgIndex=1"></section><ul><li><b><span><span leaf><span textstyle>BIIB078</span></span></span></b><b><span><span leaf><span textstyle>治疗后</span></span></span><span><span leaf><span textstyle>c9ALS</span></span></span></b><b><span><span leaf><span textstyle>患者免疫图谱分析和新型药效学生物标志物筛选</span></span></span></b><span><span leaf><span textstyle>：</span><span textstyle>为了筛选鉴定BIIB078</span></span></span><span><span leaf><span textstyle>药效评估的可靠标志物，研究人员采用了</span></span></span><b><span><span leaf><span textstyle>NULISA</span></span></span></b><span><span leaf><span textstyle>（</span></span></span><span><span leaf><span textstyle>NUcleic acid Linked Immuno-Sandwich Assay</span></span></span><span><span leaf><span textstyle>）超灵</span></span></span><span><span leaf><span textstyle>敏蛋白组学技术</span></span></span><span><span leaf><span textstyle>（该技术检测灵敏度可达fg/mL级别，同时可在uL级的临床样本中一次性系统性定量检测数百种蛋白靶标</span></span></span><span><span leaf><span textstyle>）</span></span></span><span><span leaf><span textstyle>，借助</span></span></span><b><span><span leaf><span textstyle>NULISAseq中枢神经系统检测试剂盒（120+靶标）和</span></span></span><span><span leaf><span textstyle>NULISAseq炎症和免疫检测试剂盒（250靶标)【具体检测靶标清单见文末】</span><span textstyle>，分析了6例接受BIIB078治疗的c9ALS患者的79个脑脊液</span></span></span><span><span leaf><span textstyle>（</span></span></span><span><span leaf><span textstyle>Cerebrospinal Fluid, </span></span></span><span><span leaf><span textstyle>CSF）样</span></span></span><span><span leaf><span textstyle>本，比较第一次和最后一次给药后的蛋白水平。结果发现，促炎细胞因子和细胞因子受体显著增加，包括TNFRSF11B、CSFR2B、GDF15和CCL26等。其中CCL26在所有病例和时间点表现出稳健且持续的增加，而且CCL26在两个NULISAseq Panel中呈现非常一致的结果。</span><span textstyle>经过独立免疫测定也验证了CCL26可作为BIIB078</span></span></span></b><span><span leaf><span textstyle>的药效学生物标志物。</span></span></span><section nodeleaf><img data-src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb6YhfYWCYiap9eicHTibRiaTzkqfgolxsZKg3nLxx3kiaS7soT2pLxUTtahufzOcEUL8icqp14HhmfPM4xQ/640?wx_fmt=png&amp;from=appmsg#imgIndex=2" data-ratio=0.5287037037037037 data-s=300,640 data-type=png data-w=1080 type=block data-imgfileid=100000656 src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb6YhfYWCYiap9eicHTibRiaTzkqfgolxsZKg3nLxx3kiaS7soT2pLxUTtahufzOcEUL8icqp14HhmfPM4xQ/640?wx_fmt=png&amp;from=appmsg#imgIndex=2"></section></li><li><b><span><span leaf><span textstyle>BIIB078</span></span></span></b><b><span><span leaf><span textstyle>药物在中枢神经的分布</span></span></span></b><span><span leaf><span textstyle>：</span><span textstyle>通过免疫组化、</span><span textstyle>原位杂交（RNAscope)</span><span textstyle>及板式寡核苷酸电化学发光免疫测定(POE)</span></span></span><span><span leaf><span textstyle>分析，发现</span></span></span><span><span leaf><span textstyle>BIIB078</span></span></span><span><span leaf><span textstyle>在中枢神经系统广泛分布。且给药剂量越高，组织中</span></span></span><span><span leaf><span textstyle>BIIB078</span></span></span><span><span leaf><span textstyle>浓度越高，脊髓中含量也与其它脑区浓度呈正相关性。证明了鞘内注射的</span></span></span><span><span leaf><span textstyle>BIIB078</span></span></span><span><span leaf><span textstyle>可广泛渗透中枢神经系统，分布特征也与给药时间和剂量相关。</span></span></span><p></p></li><li><b><span><span leaf><span textstyle>BIIB078</span></span></span></b><b><span><span leaf><span textstyle>治疗患者的</span></span></span><span><span leaf><span textstyle>c9orf72</span></span></span></b><b><span><span leaf><span textstyle>及相关病理标志物分析</span></span></span></b><span><span leaf><span textstyle>：</span><span textstyle>定量PCR</span></span></span><span><span leaf><span textstyle>分析发现</span></span></span><span><span leaf><span textstyle>C9orf72</span></span></span><span><span leaf><span textstyle>总转录水平在</span></span></span><span><span leaf><span textstyle>BIIB078</span></span></span><span><span leaf><span textstyle>治疗组和对照组中没有差异，内含子</span></span></span><span><span leaf><span textstyle>G</span></span></span><sub><span><span leaf><span textstyle>4</span></span></span></sub><span><span leaf><span textstyle>C</span></span></span><sub><span><span leaf><span textstyle>2</span></span></span></sub><span><span leaf><span textstyle>转录本虽然呈降低趋势但无统计学差异。用串联质谱（</span></span></span><span><span leaf><span textstyle>TMT-MS</span></span></span><span><span leaf><span textstyle>）检测</span></span></span><span><span leaf><span textstyle>C9orf72</span></span></span><span><span leaf><span textstyle>蛋白在脊髓中的丰度，</span></span></span><span><span leaf><span textstyle>ASO</span></span></span><span><span leaf><span textstyle>治疗前后也无统计变化。而且标志物</span></span></span><span><span leaf><span textstyle>poly(GP)</span></span></span><span><span leaf><span textstyle>、</span></span></span><span><span leaf><span textstyle>poly(GA)</span></span></span><span><span leaf><span textstyle>、</span></span></span><span><span leaf><span textstyle>pTDP-43</span></span></span><span><span leaf><span textstyle>以及</span></span></span><span><span leaf><span textstyle>tSTMN2</span></span></span><span><span leaf><span textstyle>的水平，在治疗组和对照组无差异，这表明</span></span></span><span><span leaf><span textstyle>BIIB078</span></span></span><span><span leaf><span textstyle>未能有效清除中枢神经系统中</span></span></span><span><span leaf><span textstyle>c9orf72</span></span></span><span><span leaf><span textstyle>毒性蛋白及相关病理指标。</span></span></span><section><span leaf><br></span></section></li></ul><p data-pm-slice="0 0 []"><b><span><span leaf><span textstyle>研究意义和展望</span></span></span></b></p><p><span leaf><span textstyle>2022 年 3 月，Biogen 和 Ionis 公司因 ASO 药物 BIIB078 未能改善渐冻症患者临床获益，宣布终止联合开发。</span></span><span leaf><span textstyle>BIIB078 虽能在部分患者中降低脑脊液 poly (GP)，但无法有效清除中枢神经系统内的 c9orf72 毒性蛋白（如 DPR、pTDP-43），且药物分布与病理改善无显著关联。</span></span><span leaf><br></span></p><p><span leaf><span textstyle>本研究通过多维度整合分析 BIIB078 治疗患者数据，在分子层面深入解析了其临床试验失败的深层机制，为渐冻症乃至神经退行性疾病治疗领域提供了宝贵的经验教训。</span></span><p></p></p><p><span leaf><span textstyle>本研究清晰地揭示了既往药效学标志物（如 poly(GP)）与大脑组织中的核心病理改变之间可能存在的巨大脱节。这表明，药物临床试验亟需更为准确、可靠、稳定的药效评估标志物。而筛选鉴定更可靠的新型标志物，需要兼具突破性灵敏度和超多重能力的蛋白组学技术。本研究正是采用了 </span><span textstyle>NULISA 技</span></span><span><span leaf><span textstyle>术</span><span textstyle>，</span></span></span><span data-pm-slice="0 0 []"><span leaf><span textstyle>借助其个位数 </span><span textstyle>fg/mL 级</span><span textstyle>的检测灵敏度</span></span></span><span><span leaf><span textstyle>、可以从</span><span textstyle>uL级的临床样本</span><span textstyle>中系统性定量检测</span><span textstyle>数百种蛋白</span><span textstyle>靶标的性能，首次在人类中枢神经系统中，系统地描绘了 A</span></span></span><span leaf><span textstyle>SO 药物可以引发的持续的、可被监测的免疫应答，并成功筛选得到了 BIIB078 的药效学生物标志物 CCL26。</span></span><span leaf><br></span></p><p><span leaf><span textstyle>NULISA 技术自 2024 年 1 月商业化以来，已经得到了逾百家研究机构和制药企业的采用，包括哈佛大学、斯坦福大学、香港科技大学、首都医学科学创新中心、赛诺菲、礼来、昱言科技、镁景科技等。我们期待NULISA技术持续在全球范围内，助力加速复杂疾病（神经退行性疾病、自身免疫性疾病等）的药物研发和临床转化进程。</span></span></p><p><span leaf><span textstyle>本研究采用了 NULISA 和 RNAscope 两项技术--这两项技术均由罗宇龄博士领衔的团队分别在 Alamar 和 ACD 公司发明和商业化。</span></span></p><p data-pm-slice="0 0 []"><strong><span leaf>参考文献</span></strong></p><p><span leaf>[1]. </span><span leaf>Zachary T. McEachin, Mingee Chung et al. </span><b><span leaf>Molecular impact of antisense oligonucleotide therapy in </span><i><span leaf>C9orf72</span></i><span leaf>-associated </span></b><b><span leaf>ALS</span></b><span leaf>. </span><span><span leaf><span textstyle>Cell</span> <span textstyle>188</span>, 1–12, November 13, 2025</span></span></p><p data-pm-slice="0 0 []"><strong><span data-pm-slice='1 1 ["para",{"tagName":"p","attributes":{"data-pm-slice":"0 0 []","style":"-webkit-tap-highlight-color: transparent; margin: 0px 0px 8px; padding: 0px; outline: 0px; max-width: 100%; box-sizing: border-box !important; overflow-wrap: break-word !important; clear: both; min-height: 1em; color: rgba(0, 0, 0, 0.9); font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif; font-size: 17px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; background-color: rgb(255, 255, 255); letter-spacing: 0.578px; line-height: 1em; visibility: visible;"},"namespaceURI":"http://www.w3.org/1999/xhtml"},"node",{"tagName":"strong","attributes":{"style":"-webkit-tap-highlight-color: transparent; margin: 0px; padding: 0px; outline: 0px; max-width: 100%; box-sizing: border-box !important; overflow-wrap: break-word !important;"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><span leaf><span textstyle>本研究采用的NULISA检测Panel靶标清单</span></span></span></strong></p><section nodeleaf data-mpa-action-id=mf1vmk49uya data-pm-slice="0 0 []"><img data-src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb5zxDdrUdGBq7iaJU2auKhlY7QsWrk9ejuQ5ibofEXeqAa4EMQ9pzX0dEiaRiav2BsLibicw1TicCfAa9nzQ/640?wx_fmt=png&amp;from=appmsg#imgIndex=3" data-ratio=0.5092592592592593 data-s=300,640 data-w=1080 type=block data-imgfileid=100000626 src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb5zxDdrUdGBq7iaJU2auKhlY7QsWrk9ejuQ5ibofEXeqAa4EMQ9pzX0dEiaRiav2BsLibicw1TicCfAa9nzQ/640?wx_fmt=png&amp;from=appmsg#imgIndex=3"></section><section nodeleaf data-mpa-action-id=mf1vmo2f3vk data-pm-slice="0 0 []"><img data-src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb5zxDdrUdGBq7iaJU2auKhlYP6X8Jv13h0qDgNaZEbDjPJJHczrvPh0SjnNRbcNVfyibaoYnro7gxEw/640?wx_fmt=png&amp;from=appmsg#imgIndex=4" data-ratio=0.5370370370370371 data-s=300,640 data-w=1080 type=block data-imgfileid=100000625 src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb5zxDdrUdGBq7iaJU2auKhlYP6X8Jv13h0qDgNaZEbDjPJJHczrvPh0SjnNRbcNVfyibaoYnro7gxEw/640?wx_fmt=png&amp;from=appmsg#imgIndex=4"></section><section mpa-from-tpl=t data-mpa-action-id=mf1vol3e149j data-pm-slice="0 0 []"><span leaf><br></span></section><section data-mpa-template=t mpa-data-temp-power-by=yiban.io mpa-from-tpl=t data-mpa-action-id=mf1vol3ertn><section data-mid mpa-from-tpl=t><section data-mid mpa-from-tpl=t><section data-mid mpa-from-tpl=t><section data-mid mpa-from-tpl=t nodeleaf><img data-src="https://mmbiz.qpic.cn/mmbiz_png/632JHKFGz4rRa4jwy8a6zPbSIB21nLXuHnMhpEwq0sHR3acL7oa4dwxCQCfDk8KVYvfokPVOswLc4OOSq9AtpQ/640?from=appmsg&amp;wx_fmt=png" data-ratio=0.8823529411764706 data-w=34 data-imgfileid=100026825 src="https://mmbiz.qpic.cn/mmbiz_png/632JHKFGz4rRa4jwy8a6zPbSIB21nLXuHnMhpEwq0sHR3acL7oa4dwxCQCfDk8KVYvfokPVOswLc4OOSq9AtpQ/640?from=appmsg&amp;wx_fmt=png"></section><section data-mid mpa-from-tpl=t><section data-mid mpa-from-tpl=t><p data-mid yb-mpa-mark=mark-main-title><span leaf>公司介绍</span><span leaf><br></span></p></section><section data-mid mpa-from-tpl=t nodeleaf><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/p4AJQW54D7cVcotID0L89pdf5QafqkzdBtok9Yk61u7koibVpbARugClaSKsDEp6t4OxWJpeLbgeLv2zukQ1T4g/640?from=appmsg&amp;wx_fmt=png" data-ratio=0.8409090909090909 data-w=88 data-imgfileid=100026824 src="https://mmbiz.qpic.cn/sz_mmbiz_png/p4AJQW54D7cVcotID0L89pdf5QafqkzdBtok9Yk61u7koibVpbARugClaSKsDEp6t4OxWJpeLbgeLv2zukQ1T4g/640?from=appmsg&amp;wx_fmt=png"></section></section><section data-mid mpa-from-tpl=t><p data-mid><span leaf>COMPANY INTRODUCTION</span><span leaf><br></span></p></section></section></section></section></section><section data-pm-slice="5 3 []"><span><strong><span><span><span leaf><br></span></span></span></strong></span></section><section data-pm-slice="5 3 []"><span><strong><span><span><span leaf><span textstyle>关于爱拉码生物（Alamar Biosciences）</span></span></span></span><span leaf><br></span></strong></span></section><section><span data-pm-slice="0 0 []"><span leaf>爱拉码生物由知名科学家、发明家罗宇龄博士（</span><span><span><span leaf>RNAscope</span><span><span leaf>™</span></span><span leaf>技术主发明人，NULISA™技术主发明人</span></span></span><span leaf>）带领团队于2018年创立，是一家创新的飞克级全自动蛋白组学平台公司，其使命是通过精准蛋白质组学实现疾病的早期检测。</span></span></section><p><span><span leaf>公司专利的NULISA</span><span><span leaf>™</span></span><span leaf>技术和ARGO™ HT自动化平台相结合，作为兼具“超灵敏”和“超多重”检测性能的突破性蛋白检测系统，在同一个平台上同时具备 “高通量蛋白质组学” 和 “聚焦蛋白标志物” 两种检测模式。借助fg/mL级的灵敏度，超多重检测能力，12个log的动态范围，全自动工作流程和一以贯之的特异性，形成了第一个有机会赋能蛋白标志物 “从发现、验证、到转化” 完整生命周期的技术平台。</span></span></p><section><span><strong><span><span><span leaf><span textstyle>联系我们</span></span></span></span></strong></span><p></p></section><section><span><span leaf>如果您希望进一步了解Alamar Biosciences的相关产品和技术，请在公众号留言，或发送电邮至：info@alamarbio.com，或请</span><span><span leaf>访问https://alamarbio.com</span></span><span leaf>。</span></span><span><span leaf>我们期待和您一起，聚焦临床需求，深挖科学问题，共同推进疾病早筛早诊和分期分型，加速精准医学的转化进程。</span></span></section><section nodeleaf><mp-common-profile data-pluginname=mpprofile data-nickname="Alamar Biosciences" data-alias=Alamar_Biosciences data-from=0 data-headimg="http://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb7vAxWdJKqUwaE4IG3TiaulQfQGwgRJpDyVSCBARV8ameiaZ2oLNbc9fECbU863SjicmR8qCvbmAGh3A/0?wx_fmt=png" data-signature="NULISA技术：超灵敏（0.2fg/mL），超多重（数百重），超宽动态范围（12个log），全自动（ARGO HT设备平台），采用一以贯之的单克隆抗体对… 真正陪伴蛋白标志物从发现到转化全生命周期！【面向转化的精准蛋白检测平台】" data-id="MzIzNTQ0ODY1OA==" data-is_biz_ban=0 data-service_type=1 data-verify_status=0></mp-common-profile></section><section><span><section><span><span leaf>↑↑↑</span><span leaf data-pm-slice='1 1 ["para",{"tagName":"section","attributes":{"style":"margin: 8px 0px;padding: 0px;outline: 0px;max-width: 100%;color: rgba(0, 0, 0, 0.9);font-size: 17px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0.544px;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;font-family: system-ui, -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);text-align: left;line-height: 1em;box-sizing: border-box !important;overflow-wrap: break-word !important;"},"namespaceURI":"http://www.w3.org/1999/xhtml"},"node",{"tagName":"span","attributes":{"style":"margin: 0px;padding: 0px;outline: 0px;max-width: 100%;color: rgb(136, 136, 136);font-size: 13px;box-sizing: border-box !important;overflow-wrap: break-word !important;"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'>欢迎关注，了解更多技术信息和资讯↑↑↑</span></span></section></span></section><section><span><span leaf><img data-src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb6AzNlZsAmM1S5Ckv6FIEicL3icrcpCBJdCeuuAUnhlwgic48JwMO6SAWjcbyq36RMZia6d4aDP5yxhQw/640?wx_fmt=png#imgIndex=5" data-ratio=0.15599343185550082 data-s=300,640 data-type=other data-w=609 data-imgfileid=100000253 src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb6AzNlZsAmM1S5Ckv6FIEicL3icrcpCBJdCeuuAUnhlwgic48JwMO6SAWjcbyq36RMZia6d4aDP5yxhQw/640?wx_fmt=png#imgIndex=5"></span></span></section><p><mp-style-type data-value=3></mp-style-type></p></div><hr><a href=https://mp.weixin.qq.com/s/CiG8m9dYAdc_-XTidhDDRg ,target=_blank rel="noopener noreferrer">原文链接</a></div><footer class=post__footer><div class="post__tags tags clearfix"><svg class="tags__badge icon icon-tag" width="16" height="16" viewBox="0 0 32 32"><path d="M4 0h8s2 0 4 2l15 15s2 2 0 4L21 31s-2 2-4 0L2 16s-2-2-2-4V3s0-3 4-3m3 10a3 3 0 000-6 3 3 0 000 6"/></svg><ul class=tags__list><li class=tags__item><a class="tags__link btn" href=../../../tags/fetched/ rel=tag>fetched</a></li><li class=tags__item><a class="tags__link btn" href=../../../tags/%E5%BE%AA%E5%9B%A0%E7%BC%89%E8%8D%AF/ rel=tag>循因缉药</a></li></ul></div></footer></article></main><div class="authorbox clearfix"><div class=authorbox__header><span class=authorbox__name>About Bloger</span></div></div><nav class="pager flex"><div class="pager__item pager__item--prev"><a class=pager__link href=../../../posts/2025-08/%E5%87%A0%E4%B9%8E%E7%BB%9D%E8%BF%B9%E7%9A%84_%E8%87%AD%E8%99%AB__%E5%BA%8A%E8%99%B1_%E5%8F%88%E5%9B%9E%E6%9D%A5%E4%BA%86__/ rel=prev><span class=pager__subtitle>«&#8201;Previous</span><p class=pager__title>几乎绝迹的“臭虫”（床虱）又回来了……</p></a></div><div class="pager__item pager__item--next"><a class=pager__link href=../../../posts/2025-09/%E7%94%9F%E4%BF%A1%E6%8A%80%E8%83%BD%E6%A0%91_x_%E6%96%B0%E6%A0%BC%E5%85%83___%E5%BC%80%E5%AD%A6%E5%AD%A3%E6%8A%80%E8%83%BD%E5%8D%87%E7%BA%A7%E6%AD%A3%E5%BD%93%E6%97%B6/ rel=next><span class=pager__subtitle>Next&#8201;»</span><p class=pager__title>生信技能树 x 新格元 | 开学季技能升级正当时</p></a></div></nav><section class=comments><div id=disqus_thread></div><script>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//kkitown.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></section></div><aside class=sidebar><div class="widget-search widget"><form class=widget-search__form role=search method=get action=https://google.com/search><input class=widget-search__field type=search placeholder=Search… name=q aria-label=Search…>
<input class=widget-search__submit type=submit value=Search>
<input type=hidden name=sitesearch value=https://ixxmu.github.io/></form></div><div class="widget-recent widget"><h4 class=widget__title>Recent Posts</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../posts/2025-09/%E9%97%B2%E9%B1%BC%E4%B8%8A%E9%82%A3%E4%BA%9B%E9%80%86%E5%A4%A9%E7%9A%84%E6%B5%8B%E5%BA%8F%E4%BB%AA/>闲鱼上那些逆天的测序仪</a></li><li class=widget__item><a class=widget__link href=../../../posts/2025-09/%E8%AF%B4%E8%B5%B7%E8%BE%9B%E8%8A%B7%E8%95%BE_%E6%88%91%E6%83%B3%E8%B5%B7%E6%97%A9%E5%B9%B4%E4%B8%80%E4%BA%9B%E5%93%81%E5%91%B3_%E7%8B%AC%E7%89%B9_%E7%9A%84%E6%81%90%E6%80%96%E7%89%87/>说起辛芷蕾，我想起早年一些品味“独特”的恐怖片</a></li><li class=widget__item><a class=widget__link href=../../../posts/2025-09/%E5%A4%9A%E6%AC%A1%E7%94%9F%E5%AD%90%E5%90%8E_28%E5%B2%81%E5%86%9C%E6%9D%91%E6%99%BA%E9%9A%9C%E5%A5%B3%E5%AD%A9%E6%82%84%E7%84%B6%E7%A6%BB%E4%B8%96/>多次生子后，28岁农村智障女孩悄然离世</a></li><li class=widget__item><a class=widget__link href=../../../posts/2025-09/openai%E7%BD%95%E8%A7%81%E5%8F%91%E8%AE%BA%E6%96%87_%E6%88%91%E4%BB%AC%E6%89%BE%E5%88%B0%E4%BA%86ai%E5%B9%BB%E8%A7%89%E7%9A%84%E7%BD%AA%E9%AD%81%E7%A5%B8%E9%A6%96/>OpenAI罕见发论文：我们找到了AI幻觉的罪魁祸首</a></li><li class=widget__item><a class=widget__link href=../../../posts/2025-09/%E5%8D%97%E4%BA%AC%E5%8D%96%E6%B7%AB%E5%A4%B4%E7%9B%AE1_34%E4%BA%BF%E6%B8%AF%E5%85%83%E8%A2%AB%E7%91%9E%E9%93%B6%E5%8E%9F%E5%89%AF%E6%80%BB%E7%9B%91%E7%A7%81%E5%90%9E/>南京卖淫头目1.34亿港元被瑞银原副总监私吞</a></li></ul></div></div><div class="widget-categories widget"><h4 class=widget__title>Categories</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../categories/duty/>Duty</a></li><li class=widget__item><a class=widget__link href=../../../categories/duty2/>Duty2</a></li></ul></div></div><div class="widget-taglist widget"><h4 class=widget__title>Tags</h4><div class=widget__content><a class="widget-taglist__link widget__link btn" href=../../../tags/cnbeta/ title=Cnbeta>Cnbeta (148)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/datawhale/ title=Datawhale>Datawhale (9)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/drpei/ title=Drpei>Drpei (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/fetched/ title=Fetched>Fetched (755)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/githubdaily/ title=GitHubDaily>GitHubDaily (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E4%B8%81%E9%A6%99%E5%9B%AD/ title=丁香园>丁香园 (30)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E4%BA%BA%E7%89%A9/ title=人物>人物 (15)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E5%8D%97%E6%96%B9%E5%91%A8%E6%9C%AB/ title=南方周末>南方周末 (11)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E5%B0%8F%E4%BC%97%E8%BD%AF%E4%BB%B6/ title=小众软件>小众软件 (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E5%B0%8F%E5%A4%A7%E5%A4%AB%E6%BC%AB%E7%94%BB/ title=小大夫漫画>小大夫漫画 (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E5%B0%91%E6%95%B0%E6%B4%BE/ title=少数派>少数派 (6)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E5%BE%AA%E5%9B%A0%E7%BC%89%E8%8D%AF/ title=循因缉药>循因缉药 (9)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E6%96%B0%E4%B9%A1%E5%9C%9F/ title=新乡土>新乡土 (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E6%98%9F%E7%90%83%E5%95%86%E4%B8%9A%E8%AF%84%E8%AE%BA/ title=星球商业评论>星球商业评论 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E6%9C%88%E5%85%89%E5%8D%9A%E5%AE%A2/ title=月光博客>月光博客 (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E6%9C%AA%E9%97%BBcode/ title=未闻Code>未闻Code (6)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E6%A7%BD%E8%BE%B9%E5%BE%80%E4%BA%8B/ title=槽边往事>槽边往事 (9)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E6%AF%8F%E6%97%A5%E4%BA%BA%E7%89%A9/ title=每日人物>每日人物 (10)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E6%B5%AA%E6%BD%AE%E5%B7%A5%E4%BD%9C%E5%AE%A4/ title=浪潮工作室>浪潮工作室 (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E6%B5%AE%E4%B9%8B%E9%9D%99/ title=浮之静>浮之静 (6)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E7%81%BC%E8%A7%81/ title=灼见>灼见 (8)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E7%86%8A%E8%A8%80%E7%86%8A%E8%AF%AD/ title=熊言熊语>熊言熊语 (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E7%94%9F%E4%BF%A1%E6%8A%80%E8%83%BD%E6%A0%91/ title=生信技能树>生信技能树 (10)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E7%94%9F%E4%BF%A1%E8%8F%9C%E9%B8%9F%E5%9B%A2/ title=生信菜鸟团>生信菜鸟团 (6)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90/ title=知识分子>知识分子 (14)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E7%BD%91%E6%98%93%E6%95%B0%E8%AF%BB/ title=网易数读>网易数读 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E8%B4%A2%E6%96%B0/ title=财新>财新 (6)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E8%B4%A2%E7%BB%8F%E4%B8%89%E5%88%86%E9%92%9F/ title=财经三分钟>财经三分钟 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E8%B5%9B%E5%85%88%E7%94%9F/ title=赛先生>赛先生 (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E9%83%91%E5%B7%9E%E6%A5%BC%E5%B8%82/ title=郑州楼市>郑州楼市 (32)</a></div><a href=../../../tags/></a></div><div class="widget-social widget"><h4 class="widget-social__title widget__title">Social</h4><div class="widget-social__content widget__content"><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Facebook rel="noopener noreferrer" href=https://facebook.com/username target=_blank><svg class="widget-social__link-icon icon icon-facebook" width="24" height="24" viewBox="0 0 352 352"><path d="m0 32v288c0 17.5 14.5 32 32 32h288c17.5.0 32-14.5 32-32V32c0-17.5-14.5-32-32-32H32C14.5.0.0 14.5.0 32zm320 0v288h-83V212h41.5l6-48H237v-31c0-14 3.5-23.5 23.5-23.5h26V66c-4.4-.6-19.8-1.5-37.5-1.5-36.9.0-62 22.2-62 63.5v36h-42v48h42v108H32V32z"/></svg>
<span>Facebook</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Twitter rel="noopener noreferrer" href=https://twitter.com/username target=_blank><svg class="widget-social__link-icon icon icon-twitter" width="24" height="24" viewBox="0 0 384 312"><path d="m384 36.9c-14.1 6.3-29.3 10.5-45.2 12.4 16.3-9.7 28.8-25.2 34.6-43.6-15.2 9-32.1 15.6-50 19.1-14.4-15.2-34.9-24.8-57.5-24.8-43.5.0-78.8 35.3-78.8 78.8.0 6.2.7 12.2 2 17.9-65.5-3.3-123.5-34.6-162.4-82.3C20 26 16.1 39.6 16.1 54c0 27.3 13.9 51.4 35 65.6-12.9-.4-25.1-4-35.7-9.9v1c0 38.2 27.2 70 63.2 77.2-6.6 1.8-13.6 2.8-20.8 2.8-5.1.0-10-.5-14.8-1.4 10 31.3 39.1 54.1 73.6 54.7-27 21.1-60.9 33.7-97.8 33.7-6.4.0-12.6-.4-18.8-1.1C34.9 299 76.3 312 120.8 312c144.9.0 224.1-120 224.1-224.1.0-3.4-.1-6.8-.2-10.2 15.4-11.1 28.7-25 39.3-40.8z"/></svg>
<span>Twitter</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Instagram rel="noopener noreferrer" href=https://www.instagram.com/username target=_blank><svg class="widget-social__link-icon icon icon-instagram" width="24" height="24" viewBox="0 0 256 256"><circle cx="193" cy="59" r="15"/><path fill-rule="evenodd" d="M101 0h54c41 0 58.4 3.9 74.5 17C256.2 37.5 256 74.8 256 97.7v60c0 26.7.0 60.4-26.5 81.4-16 13.4-33.5 16.9-74.5 16.9h-54c-41 0-57.5-3.5-74.5-16.9C1 218.9.5 186.3.1 160.5L0 155V97.7c0-23-.2-60.2 26.5-80.7C45 2 60 0 101 0zm4.9 23h44.3c45.8.0 58.3 3.5 70.3 17.5 11.8 13.2 12 30.1 12.5 62.9V156c.2 20.8.3 45.8-12.5 59.5-12 14-24.5 17.5-70.3 17.5h-44.3c-45.9.0-57.3-3.5-70.4-17.5-12.2-13-12.3-36.5-12.4-56.7v-55.6c.4-32.6.7-49.6 12.4-62.7C48 26.5 60 23 105.9 23zm19.6 144.5a42 42 0 100-84 42 42 0 000 84zm0 22.5a64.5 64.5.0 100-129 64.5 64.5.0 000 129z"/></svg>
<span>Instagram</span></a></div></div></div></aside></div><footer class=footer><div class="container footer__container flex"><div class=footer__copyright>&copy; 2025 文字轨迹.
<span class=footer__copyright-credits>Generated with <a href=https://gohugo.io/ rel="nofollow noopener" target=_blank>Hugo</a> and <a href=https://github.com/Vimux/Mainroad/ rel="nofollow noopener" target=_blank>Mainroad</a> theme.</span></div></div></footer></div><script async defer src=../../../js/menu.js></script><script src=../../../js/custom.js></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.6/MathJax.js?config=TeX-AMS-MML_HTMLorMML" async></script></body></html>